ASX:4DXHealthcare Services
Is 4DMedical’s (ASX:4DX) Global Lung Imaging Push Reframing Its Core Investment Narrative?
In late May 2026, 4DMedical launched its CLEAR clinical evidence program in the U.S. to support CT:VQ™ use in pulmonary embolism diagnosis and acquired Austria-based contextflow GmbH to add AI-driven lung imaging capabilities in Europe.
Together, these moves indicate 4DMedical is attempting to build a more comprehensive global lung imaging platform by pairing clinical validation with AI-enabled software.
We’ll now examine how the contextflow acquisition and related global expansion efforts...